| http://www.w3.org/ns/prov#value | - The product combinesNVA237, the long acting muscarinic antagonist (LAMA) licensed to Novartis by Sosei in 2005, together with Novartis??? long acting beta agonist (LABA), indacaterol, now approved in more than 80 countries, including EU, Japan and the USA.
|
